Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.058802548753096776 | N/A |
Market Cap | $863.82K | N/A |
Shares Outstanding | 14.69M | N/A |
Employees | 3.00 | N/A |